Columbia University - New York | May 20, 2020
Dr. Freedberg presented a retrospective analysis on Columbia patients on the use of Famotidine, the active ingredient in Pepcid AC, for mitigating COVID-19. The famotidine patients took a range of doses via IV (28%) or orally (72%) and they found that famotidine patients were less likely to die or be intubated.
Be the First to Know
Sign up to get updates when we add new off-label treatments, articles, videos, and clinical trials!